Origin and discovery
BPC-157 stands for Body Protection Compound-157. It is a stable synthetic pentadecapeptide — a chain of 15 amino acids — whose sequence was derived from a partial sequence identified within a larger protective protein found in human gastric juice. Rather than being a naturally circulating hormone, it is a laboratory-synthesized fragment designed to be studied on its own.
The gastric origin is more than a footnote. Much of the earliest interest grew out of gastrointestinal cytoprotection research — the stomach lining’s remarkable capacity to protect and repair itself in an acidic, enzymatically hostile environment. Investigators reasoned that a stable fragment associated with that protective system might be worth characterizing in isolation, and a substantial body of animal literature accumulated over the following decades.
It is worth framing the compound accurately from the outset. Despite widespread informal discussion, BPC-157 remains an experimental molecule. It has not completed the large, controlled human clinical trials that a therapeutic approval would require, and much of the published record is concentrated within a relatively small number of research groups working primarily in rodent models.
Structure, stability, and half-life
Structurally, BPC-157 is a short, single-chain peptide of 15 residues. What sets it apart from many research peptides is its reported stability: it is described as unusually resistant to degradation in gastric acid, whereas most peptides are rapidly broken down by the low pH and proteolytic enzymes of the digestive tract.
That acid stability is the practical reason oral research models exist at all — investigators have administered it via drinking water or oral gavage in animals and still observed effects, something that is simply not feasible with most peptides. This has made it a frequent subject in gut-focused studies where an orally available cytoprotective agent is of interest.
Stability in the stomach, however, is distinct from persistence in the bloodstream. Once absorbed, the peptide is generally reported to have a short circulating half-life, meaning it does not linger systemically for long. That pharmacokinetic profile shapes how it is dosed in the research literature, where frequent or split administration is common rather than infrequent large doses.
Proposed mechanisms of action
The mechanisms most consistently proposed in the literature revolve around blood-vessel formation. BPC-157 is reported to promote angiogenesis through the VEGFR2 (vascular endothelial growth factor receptor 2) pathway, a central signaling route for the growth of new capillaries. Improved local blood supply is a plausible common thread linking many of the tissue-repair observations, since delivery of oxygen and nutrients underpins healing.
A second recurring theme is modulation of the nitric-oxide (NO) system. Research describes interactions with NO synthesis pathways that appear context-dependent — supporting NO-related signaling in some models while counteracting disturbances in others. Because nitric oxide participates in vascular tone, cytoprotection, and inflammatory signaling, this is frequently invoked to explain the breadth of reported effects.
Additional proposed actions include the upregulation of growth-factor receptors and effects on intracellular signaling associated with cell adhesion and migration, such as the FAK-paxillin axis and early growth-response signaling. These are best understood as mechanistic hypotheses drawn from preclinical experiments rather than settled, human-confirmed pathways.
- Angiogenesis via the VEGFR2 pathway (new capillary formation).
- Modulation of the nitric-oxide system in a context-dependent manner.
- Upregulation of growth-factor receptors supporting repair signaling.
- Reported effects on cell-adhesion and migration signaling (e.g., FAK-paxillin).
Evidence broken out by tissue and context
Because the evidence base is preclinical, it is most honest to describe it tissue by tissue rather than as a single blanket claim. The gastrointestinal tract is the compound’s home turf: rodent studies have examined it in models of gastric and intestinal injury, where its cytoprotective and vascular effects are most extensively characterized. This is the context with the deepest, oldest literature.
Beyond the gut, tendon and ligament models are the most cited in the recovery community — animal experiments report accelerated healing metrics in transected or injured tendon preparations. Muscle-injury, bone, and blood-vessel models add further preclinical signals, and a separate strand of work explores nerve and central-nervous-system contexts as well as gut-brain-axis interactions.
The through-line across these tissues is improved local vascularization and cell migration in animal or in-vitro systems. What remains absent is confirmation that these effects translate to meaningful, reproducible outcomes in humans under controlled conditions. Reading the literature as promising mechanistic signal — not established clinical benefit — is the accurate posture.
- Gastrointestinal tract: the most extensively studied context (mucosal injury, cytoprotection).
- Tendon and ligament: frequently cited rodent healing models.
- Muscle, bone, and vasculature: additional preclinical repair signals.
- Nerve, CNS, and gut-brain-axis: an emerging experimental strand.
Oral versus injectable research models
Unusually for a peptide, BPC-157 appears in both oral and injectable research paradigms. Its gastric-acid stability is what enables the oral route: animal studies have delivered it through drinking water or gavage and still measured effects, which is why oral models are a genuine part of the record rather than a marketing claim.
Injectable administration is also widespread in the animal literature, typically intraperitoneal (IP) or intramuscular (IM). A distinction researchers draw is between local administration near a site of interest and systemic administration intended to reach the whole organism — the two answer different experimental questions and are not interchangeable.
For the reader, the takeaway is not a route recommendation but an understanding of why the compound is studied so flexibly. The same molecule that survives the stomach in animal models is also injected in others, and comparisons across studies must account for which route and which model were used.
Reported research dosing by context
Dosing figures in this space come from two very different sources, and conflating them is a common error. In controlled animal experiments, amounts are expressed per kilogram of body weight and are often strikingly small — on the order of roughly 10 micrograms per kilogram, with some models exploring even lower nanogram-per-kilogram ranges. These are experimental parameters chosen to probe mechanism, not human guidance.
Separately, research-community references frequently cite fixed daily amounts in the region of roughly 200 to 500 micrograms per day, often split across the day to account for the short circulating half-life, and organized into cycles of about four to six weeks. These fixed figures circulate widely but are not derived from human efficacy trials; they are conventions rather than validated protocols.
The table below contrasts these contexts so the difference is unmistakable. Everything here is reported in the literature and in research-community references; none of it constitutes a dosing recommendation, and no human-use protocol is implied.
| Research context | Reported amount | Route / frequency |
|---|---|---|
| Rodent injury models | ~10 mcg/kg (some models lower, into ng/kg) | IP or IM, often daily |
| Rodent oral models | ~10 mcg/kg equivalent in water | Oral (drinking water / gavage), continuous |
| Research-community fixed references | ~200–500 mcg/day | Frequently split across the day |
| Reported cycle length | 4–6 weeks | Followed by an off period |
Reconstitution and handling in the lab
BPC-157 is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use in research. A commonly referenced preparation combines a 10 mg vial with 2 mL of bacteriostatic water, yielding a concentration of 5,000 mcg per mL. On a standard insulin syringe, one unit equals 0.01 mL, so at that concentration one unit works out to approximately 50 mcg.
Handling conventions mirror those for other peptides: bacteriostatic water is added slowly against the vial wall rather than injected directly onto the powder, the vial is swirled rather than shaken, and the reconstituted solution is generally kept refrigerated while unopened lyophilized material is stored frozen and protected from light. These practices are about preserving peptide integrity in a laboratory setting.
This section describes material handling only. The arithmetic above is provided so researchers can interpret concentrations and the figures cited elsewhere in the literature — it is not a protocol for administration to humans.
What the research does NOT show
The single most important limitation is the absence of large, controlled human trials. The evidence base is dominated by rodent and cell studies, and encouraging animal results routinely fail to reproduce in humans across pharmacology as a whole. Efficacy and safety in people therefore remain unestablished, and BPC-157 is not a proven treatment for any condition.
A related concern is the concentration of the literature within a limited number of research groups, which raises the ordinary scientific questions of independent replication and generalizability. Long-term safety data in humans are essentially absent, and the compound’s effects on angiogenesis — while framed as beneficial for repair — warrant caution precisely because vascular signaling is a double-edged process.
Finally, because the material is sold research-use-only, product identity, purity, and dosing accuracy vary by source and are not subject to pharmaceutical-grade regulatory oversight. Any interpretation of the science should keep these gaps in full view rather than treating preclinical promise as clinical fact.
Regulatory and anti-doping status
BPC-157 is not approved by the FDA for any use. It is sold strictly for laboratory research, and it has not been through the approval pathway that would establish a defined therapeutic indication, dose, or safety profile in humans. Its legal status for other purposes varies by jurisdiction.
In competitive sport, the status is unambiguous: the World Anti-Doping Agency (WADA) added BPC-157 to its Prohibited List in 2022, classifying it under category S0 (non-approved substances) — a catch-all covering pharmacological agents not addressed elsewhere and lacking approval for human therapeutic use. It is prohibited at all times, in and out of competition.
For athletes subject to testing, this means use carries a real risk of sanction. For everyone else, the S0 listing is a useful signal of exactly how regulators view the molecule today: an unapproved, still-experimental compound rather than an accepted therapy.